Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at Stifel CNS Days (Virtual) Transcript

Mar 29, 2022 / 08:00PM GMT
Release Date Price: €31.55 (+5.91%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much, everyone, for joining in this later afternoon panel with Sage Therapeutics. With me is CEO, Barry Greene, who I'm sure everyone listening in knows well. Barry, assuming everyone knows Sage well, maybe you can just offer some introductory remarks, a couple of high-level updates, and we can get into Q&A. Does that work?

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes. Sounds great, Paul. And I just want to thank you and Stifel for having us here today.

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Awesome. So please.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes, please. So thank you. Look, as all of you know, at Sage, we've developed deep expertise in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot